Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.34 |
| ▸ | FLT1 | P17948 | 2/20 | 0.34 |
| ▸ | LTK | P29376 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082129 | 0.80 | ALDH1A1 (0.38) | MMP12CYP11B1CYP11B2PARP1ALDH1A1 | |
| SCHEMBL7958200 | 0.80 | MMP12 (0.38) | MMP12CYP11B1CYP11B2PARP1ALDH1A1 | |
| SCHEMBL18307151 | 0.80 | MMP12 (0.38) | MMP12CYP11B1CYP11B2PARP1ALDH1A1 | |
| SCHEMBL15979057 | 0.80 | NR3C2 (0.39) | MMP12CYP11B1CYP11B2NR3C2 | |
| SCHEMBL10283759 | 0.80 | MMP12 (0.49) | MMP12CYP11B1CYP11B2PARP1ALDH1A1 | |
| SCHEMBL17095009 | 0.78 | PARP1 (0.37) | MMP12CYP11B1CYP11B2PARP1ALDH1A1 | |
| SCHEMBL13748940 | 0.76 | MMP12 (0.39) | MMP12CYP11B1CYP11B2PARP1ALDH1A1 | |
| SCHEMBL7326455 | 0.76 | PARP1 (0.39) | MMP12CYP11B1CYP11B2PARP1ALDH1A1 | |
| SCHEMBL21382790 | 0.76 | GRM5 (0.36) | MMP12CYP11B1CYP11B2PARP1ALDH1A1 | |
| SCHEMBL14804046 | 0.76 | MMP12 (0.39) | MMP12CYP11B1CYP11B2PARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867556-B | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12139474-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-118852196-A | CYP11B2 inhibitor compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240002367-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-04 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11702407-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702407-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210380561-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-0357675-A4 | PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | — | 1992-01-15 | — | — | EP | disclosed |
| WO-1991006300-A1 | NAPHTHERIDINONE- AND PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING SAME, AND THEIR USES | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| US-5015638-A | Cardiovascular disorders, cardiotonic agents for congestive he art failure | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0357675-A1 | PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4906629-A | Pyridazinone and pyrazolone compounds, cardiotonic compositions including same, and their uses | RORER PHARMACEUTICAL CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| US-4866074-A | Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same, and their uses | RORER PHARMACEUTICAL CORPORATION (US) | 1989-09-12 | — | — | US | disclosed |
| US-4829066-A | CONGESTIVE HEART FAILURE | RORER PHARMACEUTICAL CORPORATION (US) | 1989-05-09 | — | — | US | disclosed |
| US-4822794-A | Pyridooxazinone-pyridone compounds, cardiotonic compositions including the same, and their uses | RORER PHARMACEUTICAL CORPORATION (US) | 1989-04-18 | — | — | US | disclosed |
| WO-1988008706-A1 | PYRIDOOXAZINONE-PYRIDAZINONE AND PYRAZOLONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USE | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1988-11-17 | — | — | WO | disclosed |
| WO-1988008705-A1 | PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1988-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702407-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | MMP12 859/4885CYP11B1 2557/4885CYP11B2 2738/4885 |
| US-12139474-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | MMP12 831/4885CYP11B1 2563/4885CYP11B2 2752/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | MMP12 4193/4885CYP11B1 713/4885CYP11B2 445/4885 |
| US-20240002367-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | MMP12 831/4885CYP11B1 2563/4885CYP11B2 2752/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | MMP12 4193/4885CYP11B1 713/4885CYP11B2 445/4885 |
| US-20210380561-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | MMP12 859/4885CYP11B1 2557/4885CYP11B2 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.